Alternatively Activated Macrophage Possess Antitumor Cytotoxicity That is Induced by IL-4 and Mediated by Arginase-1
Overview
Affiliations
Earlier studies have shown that the adoptive transfer of Th2-polarized CD4 T cells can clear established tumors from mice in an antigen-specific manner. Although eosinophils were implicated in this process, the exact mechanism of tumor clearance and which immune effector cells were involved, remain to be defined. Consequently, experiments were undertaken to elucidate the mechanism of Th2-mediated destruction of B16-F1 melanoma cells by examining the in vitro antitumor activity of leukocytes within a type-2 inflammatory infiltrate. The experimental data show that activation of alternatively activated macrophages (aaMacs) within type-2 infiltrates by IL-4 or IL-13 can inhibit B16-F1 melanoma cell proliferation through a mechanism that is dependent on arginase-1 depletion of L-arginine within the tumor cell microenvironment. Interestingly, whilst at higher E:T ratios aaMac exhibited antitumor activity, at lower E:T ratios aaMacs were observed to enhance rather than inhibit B16-F1 melanoma cell growth. This highlights the fine balance between stimulating the antitumorigenic and protumorigenic properties of aaMacs in tumor immunotherapy protocols.
Wojtowicz E, Hampton K, Moreno-Gonzalez M, Utting C, Lan Y, Ruiz P Commun Biol. 2024; 7(1):1219.
PMID: 39349819 PMC: 11444042. DOI: 10.1038/s42003-024-06932-w.
Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy.
Kang X, Huang Y, Wang H, Jadhav S, Yue Z, Tiwari A Pharmaceutics. 2024; 16(1).
PMID: 38258072 PMC: 10819517. DOI: 10.3390/pharmaceutics16010061.
Ou Y, Yang Y, Li X, Zhang X, Zhao L, Yang C Cancer Med. 2023; 12(15):16444-16454.
PMID: 37366304 PMC: 10469818. DOI: 10.1002/cam4.6287.
WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer.
Du W, Menjivar R, Donahue K, Kadiyala P, Velez-Delgado A, Brown K J Exp Med. 2022; 220(1).
PMID: 36239683 PMC: 9577101. DOI: 10.1084/jem.20220503.
Cristiani C, Capone M, Garofalo C, Madonna G, Mallardo D, Tuffanelli M Front Immunol. 2022; 13:811131.
PMID: 35173725 PMC: 8841353. DOI: 10.3389/fimmu.2022.811131.